anidulafungin

Anidulafungin is a semi-synthetic lipopeptide antifungal drug of the echinocandin class, used primarily for the treatment of invasive Candida infections, including candidemia (fungal infection in the blood), intra-abdominal abscess and peritonitis, and esophageal candidiasis. It acts by inhibiting the synthesis of 1,3-beta-D-glucan, an essential component of fungal cell walls. This mechanism disrupts fungal cell wall integrity and leads to cell death. Anidulafungin is administered intravenously as a powder for solution and is indicated for use in adults and children at least 1 month old[1][2][3][5]. The drug was originally developed by Eli Lilly Pharmaceuticals, later licensed to Versicor (which became Vicuron), and subsequently acquired by Pfizer[6]. It received FDA approval in February 2006[6].

Brand names

EraxisEcalta

Other names

anidulafungin